https://www.bio-nauta.com/blog-3-1 daily 0.75 2025-03-04 https://www.bio-nauta.com/blog-3-1/blog-post-title-one-4tkt4 monthly 0.5 2020-05-19 https://www.bio-nauta.com/blog-3-1/blog-post-title-two-rwbay monthly 0.5 2020-05-19 https://www.bio-nauta.com/blog-3-1/blog-post-title-three-k5rna monthly 0.5 2020-05-19 https://www.bio-nauta.com/blog-3-1/blog-post-title-four-3cnnw monthly 0.5 2020-05-19 https://www.bio-nauta.com/articles daily 0.75 2026-02-14 https://www.bio-nauta.com/articles/cssdna-as-the-next-frontier-in-genetic-medicine monthly 0.5 2026-02-14 https://www.bio-nauta.com/articles/beyond-the-cage-how-the-fda-modernization-act-is-accelerating-the-shift-toward-human-based-models monthly 0.5 2026-02-14 https://www.bio-nauta.com/articles/the-superbug-wars monthly 0.5 2025-09-29 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/9bdd5883-7f29-4611-b072-af2e4101bbdb/Superbugs_EmergingSolutions.png Articles - The Superbug Wars - Make it stand out Three emerging solutions for antibiotic-resistant bacteria. Phage therapy: bacteriophages are introduced into the patient, where they specifically infect resistant bacteria, replicate, and kill them by bursting the cells. Chemokines: these molecules have bactericidal properties by binding to bacterial membranes, creating pores that disrupt permeability and ultimately kill the cell. Far-UVC light: more than a treatment, this is a safe sterilization tool that prevents the spread of resistant bacteria and viruses in public spaces. It kills microbes by damaging their DNA but is harmless to humans because it cannot penetrate beyond the outer dead layer of skin. https://www.bio-nauta.com/articles/undruggable-no-more monthly 0.5 2025-08-25 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/db1158df-8939-4e37-a59c-c2f687dc092d/Strategies_target_undruggable2.png Articles - Undruggable No More - Make it stand out Strategies to tackle “undruggable” proteins. A variety of approaches can be used to interfere with disease processes driven by proteins that are difficult—or so far impossible—to drug. These include: (1) targeting upstream signaling pathways, (2) blocking transcription, (3) modulating modifying enzymes, (4) disrupting protein–protein interactions, (5) altering localization, (6) preventing aggregation, (7) targeted degradation (8) monoclonal antibodies (9) targeting condensates for disordered proteins. https://www.bio-nauta.com/articles/unleashing-the-future-of-therapeutics-antibody-discovery monthly 0.5 2025-07-30 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/3ff97842-8abe-472a-9a16-60432a7ef66c/Antibody_structure.png Articles - Unleashing the Future of Therapeutics: Antibody Discovery - Make it stand out Antibodies are Y-shaped proteins composed of two identical heavy chains and two identical light chains. Each chain includes an N-terminal variable domain, responsible for antigen recognition, and one or more C-terminal constant domains that define the antibody's class and function. At the tips of the "Y" lie the variable regions (Fab regions), where sequence diversity enables recognition of a vast range of antigens. Within these regions are complementarity-determining regions (CDRs)—three per chain—that directly contact the antigen. The base of the Y forms the constant region (Fc region), which interacts with components of the immune system to mediate effector functions such as phagocytosis or cell lysis. The chains are held together by disulfide bonds—between the two heavy chains and between each heavy and light chain—stabilizing the antibody’s structure. https://www.bio-nauta.com/articles/the-living-lab-bench-the-role-of-3d-bioprinting-in-smarter-drug-development monthly 0.5 2025-09-29 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/8497a3c6-0883-474b-9258-6e73f2e4d58e/3Dbioprinting.png Articles - The Living Lab Bench: The Role of 3D Bioprinting in Smarter Drug Development - Make it stand out This illustration highlights the core applications of 3D bioprinting in biomedical research. By enabling the creation of human-relevant tissue models, 3D bioprinting is accelerating drug discovery and improving the accuracy of preclinical testing. It also opens new avenues for personalized medicine using patient-derived tissues and supports regenerative medicine through functional implants, such as cardiac patches. https://www.bio-nauta.com/articles/inside-the-cell-how-cell-based-assays-reveal-drug-function monthly 0.5 2025-05-21 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/7c001a33-df59-4882-a99f-fa79c8982cd2/cell_based_assays.png Articles - Inside the Cell: How Cell-Based Assays Reveal Drug Function - Make it stand out A visual guide to the key questions we ask in cell-based assays: Does the drug bind its target? Does it activate or block a pathway? Can it degrade a protein, keep the cell alive, or change where proteins go? Each assay type gives us a piece of the puzzle—together, they reveal the full story of how a drug behaves inside a living cell. https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/95ff0a8b-10f5-42db-8a22-05cd91da4de2/Biocehmical+vs+cell+based+assays.png Articles - Inside the Cell: How Cell-Based Assays Reveal Drug Function - Make it stand out A side-by-side comparison of biochemical and cell-based assays, highlighting how each contributes unique insights to drug discovery. While biochemical assays offer precise control and clarity, cell-based assays provide context and complexity—making them complementary tools in understanding drug function. https://www.bio-nauta.com/articles/engineering-protein-location monthly 0.5 2025-09-29 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/2fa390ff-7f19-4f81-b710-d9d6f34be16f/Cell+with+Vesicular+System+%28Layout%29-3.png Articles - Engineering Protein Localization - A cell with various compartments, highlighting subcellular protein trafficking. p53 moves from the cytosol to the nucleus, where it functions as a tumor suppressor by regulating gene expression. Rhodopsin, a membrane protein, is trafficked to the cell surface, while a mutant version remains stuck in the ER. CFTR follows a similar pattern, with normal trafficking to the cell surface and mutant CFTR accumulating in the ER, representing cystic fibrosis pathology. Ras, an oncogene, relocates from the cytosol to the cell membrane, where it becomes active through lipid molecule addition, triggering signaling pathways associated with cancer progression. The illustration shows a cell with various compartments, highlighting subcellular protein trafficking. p53 moves from the cytosol to the nucleus, where it functions as a tumor suppressor by regulating gene expression. Rhodopsin, a membrane protein, is trafficked to the cell surface, while a mutant version remains stuck in the ER. CFTR follows a similar pattern, with normal trafficking to the cell surface and mutant CFTR accumulating in the ER, representing cystic fibrosis pathology. Ras, an oncogene, relocates from the cytosol to the cell membrane, where it becomes active through lipid molecule addition, triggering signaling pathways associated with cancer progression. https://www.bio-nauta.com/articles/the-promise-of-in-womb-treatment monthly 0.5 2025-09-29 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/e5684a74-4a96-4004-9b7e-aeefff192a4b/Gene+Splicing-3.png Articles - The Promise of In-Womb Treatment: A New Frontier in Treating Genetic Disorders Before Birth - The central dogma of molecular biology & RNA splicing explained: Genetic information (DNA) is used in our cells to produce proteins, which carry out essential functions. DNA acts as a vast library and contains many books (genes), each gene is copied into an mRNA molecule that serves as a concise summary of a specific book or gene, and ribosomes use this information to assemble a protein. This process ensures that cells function properly and that proteins like SMN are produced as needed. But before the ribosomes make the protein the mRNA molecule is processed, that’s called RNA splicing, a cellular process that removes non-coding segments (introns) from a gene transcript, leaving only the essential coding parts (exons). In the case of the SMN2 gene, a crucial exon (exon 7) is often skipped, leading to a truncated and non-functional protein. This splicing error is the key issue in SMA, and treatments aim to correct it. https://www.bio-nauta.com/articles/category/Drug+Discovery+%26+Biomedical+Techniques monthly 0.5 https://www.bio-nauta.com/articles/category/Emerging+Technologies monthly 0.5 https://www.bio-nauta.com/articles/category/Emerging+Treatments monthly 0.5 https://www.bio-nauta.com/articles/tag/tissue+engineering monthly 0.5 https://www.bio-nauta.com/articles/tag/next-generation+biologics monthly 0.5 https://www.bio-nauta.com/articles/tag/regenerative+medicine monthly 0.5 https://www.bio-nauta.com/articles/tag/Lab+life monthly 0.5 https://www.bio-nauta.com/articles/tag/reduction+of+animal+testing monthly 0.5 https://www.bio-nauta.com/articles/tag/Cell-based+assays monthly 0.5 https://www.bio-nauta.com/articles/tag/future+of+antibiotics monthly 0.5 https://www.bio-nauta.com/articles/tag/organs-on-chips monthly 0.5 https://www.bio-nauta.com/articles/tag/antimicrobial+resistance monthly 0.5 https://www.bio-nauta.com/articles/tag/in+vitro+models monthly 0.5 https://www.bio-nauta.com/articles/tag/antibody+discovery monthly 0.5 https://www.bio-nauta.com/articles/tag/MRSA monthly 0.5 https://www.bio-nauta.com/articles/tag/organ-on-a-chip monthly 0.5 https://www.bio-nauta.com/articles/tag/antibody-drug+conjugates monthly 0.5 https://www.bio-nauta.com/articles/tag/preclinical+testing+alternatives monthly 0.5 https://www.bio-nauta.com/articles/tag/Protein%E2%80%93protein+interactions monthly 0.5 https://www.bio-nauta.com/articles/tag/organoids monthly 0.5 https://www.bio-nauta.com/articles/tag/FDA+Modernization+Act+2.0 monthly 0.5 https://www.bio-nauta.com/articles/tag/drug+development monthly 0.5 https://www.bio-nauta.com/articles/tag/Novel+therapeutics monthly 0.5 https://www.bio-nauta.com/articles/tag/gene+therapy monthly 0.5 https://www.bio-nauta.com/articles/tag/PROTACs monthly 0.5 https://www.bio-nauta.com/articles/tag/therapeutic+antibodies monthly 0.5 https://www.bio-nauta.com/articles/tag/antibody+engineering monthly 0.5 https://www.bio-nauta.com/articles/tag/single-stranded+DNA monthly 0.5 https://www.bio-nauta.com/articles/tag/phage+therapy monthly 0.5 https://www.bio-nauta.com/articles/tag/Reporter+gene+assay monthly 0.5 https://www.bio-nauta.com/articles/tag/Biotech+blog monthly 0.5 https://www.bio-nauta.com/articles/tag/Drug+discovery monthly 0.5 https://www.bio-nauta.com/articles/tag/antimicrobial+solutions monthly 0.5 https://www.bio-nauta.com/articles/tag/human-based+models monthly 0.5 https://www.bio-nauta.com/articles/tag/Gene+replacement monthly 0.5 https://www.bio-nauta.com/articles/tag/Candida+auris monthly 0.5 https://www.bio-nauta.com/articles/tag/Biomedical+research monthly 0.5 https://www.bio-nauta.com/articles/tag/AI+in+drug+discovery monthly 0.5 https://www.bio-nauta.com/articles/tag/DNA+origami monthly 0.5 https://www.bio-nauta.com/articles/tag/bacteriophage monthly 0.5 https://www.bio-nauta.com/articles/tag/nucleic+acid+therapeutics monthly 0.5 https://www.bio-nauta.com/articles/tag/New+Approach+Methodologies monthly 0.5 https://www.bio-nauta.com/articles/tag/biologics+in+medicine monthly 0.5 https://www.bio-nauta.com/articles/tag/Covalent+inhibitors monthly 0.5 https://www.bio-nauta.com/articles/tag/antibiotic+resistance monthly 0.5 https://www.bio-nauta.com/articles/tag/superbugs monthly 0.5 https://www.bio-nauta.com/articles/tag/immunotherapy monthly 0.5 https://www.bio-nauta.com/articles/tag/DNA+nanotechnology monthly 0.5 https://www.bio-nauta.com/articles/tag/Mechanism+of+action monthly 0.5 https://www.bio-nauta.com/articles/tag/FAR-UV+light monthly 0.5 https://www.bio-nauta.com/articles/tag/ex+vivo+human+tissue monthly 0.5 https://www.bio-nauta.com/articles/tag/CRISPR monthly 0.5 https://www.bio-nauta.com/articles/tag/AI+drug+discovery monthly 0.5 https://www.bio-nauta.com/articles/tag/undruggable+proteins monthly 0.5 https://www.bio-nauta.com/articles/tag/FDA+roadmap+reducing+animal+testing monthly 0.5 https://www.bio-nauta.com/articles/tag/multidrug-resistant+bacteria monthly 0.5 https://www.bio-nauta.com/articles/tag/3D+bioprinting monthly 0.5 https://www.bio-nauta.com/articles/tag/chemokines monthly 0.5 https://www.bio-nauta.com/articles/tag/personalized+medicine monthly 0.5 https://www.bio-nauta.com/articles/tag/CDC+superbugs monthly 0.5 https://www.bio-nauta.com/articles/tag/genetic+medicine monthly 0.5 https://www.bio-nauta.com/articles/tag/Targeted+protein+degradation monthly 0.5 https://www.bio-nauta.com/articles/tag/Drugging+the+undruggable monthly 0.5 https://www.bio-nauta.com/articles/tag/bispecific+antibodies monthly 0.5 https://www.bio-nauta.com/articles/tag/CAR-T+therapy monthly 0.5 https://www.bio-nauta.com/articles/tag/monoclonal+antibodies monthly 0.5 https://www.bio-nauta.com/contact daily 0.75 2025-03-25 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/1726013120.266633-ADKMEXCSPCKBBMTETDUA/imgg-od3-dz0szzgq.png https://www.bio-nauta.com/about daily 0.75 2025-08-15 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/429b471a-7cf1-4a80-a9cf-88ecc41be1ac/DSC_6424.jpg https://www.bio-nauta.com/home daily 1.0 2025-08-27 https://images.squarespace-cdn.com/content/v1/67c75bb366a2fe68a0feea27/b8c35e01-576b-4cb6-9df5-9c17cc2a0f44/Screenshot+2025-03-04+at+10.46.21%E2%80%AFPM.png